Comparison
3 Methylglutaconic Aciduria Type 4 C1855126 vs 17p11 2 Microduplication Syndrome C2931246
Clinical comparison between 3 Methylglutaconic Aciduria Type 4 and 17p11 2 Microduplication Syndrome for differential diagnosis and treatment planning.
3 Methylglutaconic Aciduria Type 4 C1855126
A metabolic disorder affecting the nervous system that typically begins in childhood. Patients may experience movement difficulties, muscle stiffness, and developmental challenges. Care involves supportive therapies and symptom management.
17p11 2 Microduplication Syndrome C2931246
A chromosomal condition involving duplication on chromosome 17, related to Potocki-Lupski syndrome. Features often include developmental delays, learning challenges, and distinctive facial features.
6 comparison axes
Onset
3 Methylglutaconic Aciduria Type 4 C1855126
0-null
17p11 2 Microduplication Syndrome C2931246
0-null
Onset patterns differ
Severity
3 Methylglutaconic Aciduria Type 4 C1855126
severe
17p11 2 Microduplication Syndrome C2931246
moderate
Different severity levels
Chronic
3 Methylglutaconic Aciduria Type 4 C1855126
Chronic
17p11 2 Microduplication Syndrome C2931246
Chronic
Differing course
Communicable
3 Methylglutaconic Aciduria Type 4 C1855126
No
17p11 2 Microduplication Syndrome C2931246
No
Different transmission
Body System
3 Methylglutaconic Aciduria Type 4 C1855126
metabolic
17p11 2 Microduplication Syndrome C2931246
congenital
Same/different system
Category
3 Methylglutaconic Aciduria Type 4 C1855126
metabolic
17p11 2 Microduplication Syndrome C2931246
genetic
Different category
Bottom line
3-methylglutaconic-aciduria-type-4-C1855126 and 17p11-2-microduplication-syndrome-C2931246 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Methylglutaconic Aciduria Type 4 C1855126 | 17p11 2 Microduplication Syndrome C2931246 | Discriminating power |
|---|---|---|---|
| Movement and muscle tone | Movement difficulty and muscle stiffness are described. | Not established as core features in the supplied description. | Moderate |
| Development and learning | Developmental challenges may occur, often beginning in childhood. | Developmental delay and learning challenges are commonly described. | Low |
| Physical appearance | Distinctive facial features are not established here. | Distinctive facial features are often reported. | Moderate |
When to favor each condition
Choose 3 Methylglutaconic Aciduria Type 4 C1855126 when
Childhood neurologic symptoms with suspected metabolic disease
The supplied profile emphasizes nervous-system involvement and supportive metabolic care.
Moderate
Abnormal organic-acid findings needing diagnosis
An abnormal metabolite result is not itself this diagnosis and requires specialist confirmation.
High
No chromosomal duplication identified
A negative chromosomal test does not exclude a metabolic disorder.
Moderate
Choose 17p11 2 Microduplication Syndrome C2931246 when
Developmental delay with suspected chromosomal syndrome
The condition is defined by duplication at 17p11.2 and is related to Potocki-Lupski syndrome.
High
Learning difficulties with distinctive facial features
These features fit the supplied congenital description better than the metabolic profile.
Moderate
Family or prenatal genetic evaluation
A chromosomal finding may guide genetic counseling, but clinical correlation remains necessary.
Moderate
How key tests differ
| Test | 3 Methylglutaconic Aciduria Type 4 C1855126 | 17p11 2 Microduplication Syndrome C2931246 | Interpretation |
|---|---|---|---|
| Urine organic acids | May show abnormal 3-methylglutaconic acid; exact cutoffs are not established here. | No characteristic organic-acid pattern is established. | An abnormal result suggests metabolic evaluation, not a definitive diagnosis. |
| Chromosomal microarray | No defining 17p11.2 duplication is expected. | May identify duplication at 17p11.2. | A confirmed duplication supports the chromosomal diagnosis when clinically correlated. |
| Neurologic assessment | May document movement difficulty, stiffness, or developmental concerns. | May document developmental and learning differences. | Findings overlap and cannot distinguish the conditions alone. |
Prognosis comparison
3 Methylglutaconic Aciduria Type 4 C1855126
- Outcome
- Described as severe and chronic, but individual outcome is not established.
- Factors
- Neurologic involvement, developmental needs, and response to supportive care may influence course.
17p11 2 Microduplication Syndrome C2931246
- Outcome
- Described as moderate and chronic, with substantial individual variation.
- Factors
- Developmental profile, learning needs, and associated features may influence outcome.
Time frame: Often recognized in childhood; long-term course is not established from these data.
Diagnosis confirmation, comorbidities, therapies, and family support affect outlook.
Complications comparison
| Complication | Presentation |
|---|---|
| Neurologic impairment | Movement and tone problems may affect function. Neurologic complications are not specifically established here. Severity and progression require individual assessment. |
| Developmental disability | Developmental challenges may occur. Developmental delay and learning difficulty are prominent. Support needs vary and are not predictable from these descriptions. |
| Associated congenital features | Not established in the supplied data. Distinctive facial features may be present. Additional organ involvement should not be assumed without evaluation. |
Patient education highlights
- HighDifferent causes
One is a metabolic condition and the other a chromosomal duplication; neither is communicable.
- HighTesting limits
Laboratory or genetic results need specialist interpretation and do not replace clinical assessment.
- MediumSupportive care
Care is generally supportive and individualized; no treatment dose or outcome can be inferred here.